Last update 23 Nov 2024
[177Lu]-LNC1011
Last update 23 Nov 2024
Overview
Basic Info
Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms 177Lu-DansyI-PSMA, 177Lu-LNC1011 |
Target |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with [177Lu]-LNC1011An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-Dansyl-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 Trial Assessing Safety, Maximum Tolerated Dose, and Patient-Specific Dosimetry of [177Lu]Lu-LNC1011 in Metastatic Castration-Resistant Prostate
评价 177Lu-LNC1011 注射液在前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC）患者中的安全性、耐受性、药代动力学、辐射剂量学和初步疗效的I/II 期临床试验
[Translation] A phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry and preliminary efficacy of 177Lu-LNC1011 injection in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)
100 Clinical Results associated with [177Lu]-LNC1011
Login to view more data
100 Translational Medicine associated with [177Lu]-LNC1011
Login to view more data
100 Patents (Medical) associated with [177Lu]-LNC1011
Login to view more data
100 Deals associated with [177Lu]-LNC1011
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| PSMA-Positive Castration-Resistant Prostatic Cancer | Phase 2 | CN | 12 Nov 2024 | |
| Metastatic castration-resistant prostate cancer | Phase 1 | CN | 05 Apr 2024 | |
| PSMA-Positive Prostatic Cancer | IND Approval | US | 02 Jul 2024 | |
| Solid tumor | Preclinical | - | 25 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | [177Lu]Lu-LNC1011 1.85 GBq | znscproybw(alqcjhqjrz) = No life-threatening adverse events were observed during the dosing observation period svynzsjdyr (ixplugxpmw ) View more | - | 09 Jun 2024 | ||
[177Lu]Lu-LNC1011 3.7 GBq |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free